peripheral arterial occlusive disease / bloodletting

Discussion in 'Health and medical' started by Doe, Mar 25, 2004.

  1. Doe

    Doe Guest

    Schweiz Med Wochenschr. 1989 Dec 23;119(51):1862-7. Related Articles, Links

    [Hemodilution in patients with multiple morbidity and
    peripheral arterial occlusive disease]

    [Article in German]

    Kiesewetter H, Blume J, Jung F, Spitzer S, Bach R, Birk A,
    Schieffer H, Wenzel

    Abteilung fur Klinische Hamostaseologie und
    Transfusionsmedizin Universitat des Saarlandes, Homburg-
    Saar, BRD.

    The treatment of multi-morbid patients suffering from
    peripheral arterial occlusive disease (PAOD) is rendered
    difficult due to concomitant diseases such as coronary heart
    disease, chronic obstructive pulmonary affection, arterial
    hypertension or diabetes mellitus. Haemodilution can be a
    clinically efficient therapy for some of the concomitant
    diseases as well. It is, however, necessary to use a weak
    colloidal solution which has no additional volume effect as
    an iso-oncotic substance. Hydroxyethyl starch 200/0.5 6%
    meets all these demands. In a double-blind, placebo-
    controlled study over a period of 6 weeks a marked and
    significant increase of almost 40% in painfree walking
    distance was achieved for 19 of 37 multi-morbid patients
    with PAOD II by moderate hypervolaemic haemodilution with
    venesections. Besides the clinical improvement, blood
    fluidity also increased through a reduction in haematocrit,
    plasma viscosity, and erythrocyte aggregation.

    Publication Types: Clinical Trial Controlled Clinical Trial
    Randomized Controlled Trial

    PMID: 2481883 [PubMed - indexed for MEDLINE]


    Who loves ya. Tom Jesus Was A Vegetarian! Man Is A Herbivore! DEAD

Share This Page